Dr. Levis on the Ideal Use of Quizartinib in FLT3-ITD AML

Mark J. Levis, MD, PhD
Published: Wednesday, Feb 05, 2014

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

The ideal way to use a FLT3 inhibitor is to introduce it upfront with induction therapy in a newly diagnosed patient with FLT3-ITD AML, Levis says. Studies using FLT3 inhibitors that are not as effective still show a considerable amount of efficacy with this procedure.

Patients should be treated into remission and until the patient can receive an allogeneic transplant and then a FLT3 inhibitor. Levis says this method could lead to a quantum shift in the survival of patients with this disease.

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

The ideal way to use a FLT3 inhibitor is to introduce it upfront with induction therapy in a newly diagnosed patient with FLT3-ITD AML, Levis says. Studies using FLT3 inhibitors that are not as effective still show a considerable amount of efficacy with this procedure.

Patients should be treated into remission and until the patient can receive an allogeneic transplant and then a FLT3 inhibitor. Levis says this method could lead to a quantum shift in the survival of patients with this disease.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x